

**Supplementary Table 4.** Subgroup analysis of studies using Cohen's kappa

| Imaging feature                     | Studies using Cohen's kappa |                       |           | All included studies |                       |           |
|-------------------------------------|-----------------------------|-----------------------|-----------|----------------------|-----------------------|-----------|
|                                     | Number of studies           | Pooled kappa (95% CI) | $I^2$ (%) | Number of studies    | Pooled kappa (95% CI) | $I^2$ (%) |
| Rim arterial phase hyperenhancement | 21                          | 0.71 (0.63-0.78)      | 89.0      | 24                   | 0.72 (0.65-0.78)      | 91.0      |
| Peripheral washout                  | 18                          | 0.55 (0.41-0.68)      | 85.2      | 20                   | 0.52 (0.39-0.65)      | 95.3      |
| Delayed central enhancement         | 17                          | 0.63 (0.53-0.74)      | 85.5      | 20                   | 0.60 (0.50-0.70)      | 93.2      |
| Targetoid restriction               | 15                          | 0.70 (0.57-0.83)      | 93.2      | 18                   | 0.68 (0.57-0.78)      | 96.5      |
| Targetoid TP or HBP appearance      | 16                          | 0.78 (0.70-0.87)      | 91.3      | 19                   | 0.74 (0.65-0.83)      | 98.0      |
| Infiltrative appearance             | 11                          | 0.62 (0.46-0.78)      | 90.0      | 12                   | 0.64 (0.49-0.78)      | 89.2      |
| Marked diffusion restriction        | 10                          | 0.45 (0.22-0.68)      | 98.0      | 12                   | 0.49 (0.30-0.68)      | 97.7      |
| Necrosis or severe ischemia         | 13                          | 0.56 (0.43-0.69)      | 89.8      | 15                   | 0.61 (0.48-0.73)      | 91.1      |

CI, confidence interval; TP, transitional phase; HBP, hepatobiliary phase.